← Leaderboards
Maria R Baer
Roswell Park Cancer Institute Corp
$1,593,414
Attributed
$1,593,414
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $192.6K · FY2007–24$200K$150K$100K$50K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,593,414 · 5
VA$0 · 2
By mechanism
R21$1,171,221 · 3
P30$422,193 · 2
I01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Heinz Baumann$4,783,902
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTreatment OutcomePatient-Focused OutcomesDiagnosisCell LineResponseBasePre-ClinicalClinical TrialsSamplingChemotherapyProteinsIn VitroRelapseMedicalIn VivoCellsMediatingResistancePharmaceutical PreparationsCollegeCancer TherapyGrantAdvisory Committees
Grant awards (23)
Enhancing FLT3 inhibitor efficacy in acute myeloid leukemia with FLT3-ITD$0
I01 · FY2024 · VA · contact PI
Enhancing FLT3 inhibitor efficacy in acute myeloid leukemia with FLT3-ITD$0
I01 · FY2023 · VA · contact PI
Experimental Therapeutics Program$48,982
P30 · FY2022 · CA · contact PI
Enhancing FLT3 inhibitor efficacy in acute myeloid leukemia with FLT3-ITD$0
I01 · FY2022 · VA · contact PI
Experimental Therapeutics Program$48,982
P30 · FY2021 · CA · contact PI
Enhancing FLT3 inhibitor efficacy in acute myeloid leukemia with FLT3-ITD$0
I01 · FY2021 · VA · contact PI
Experimental Therapeutics (ET)$48,553
P30 · FY2020 · CA · contact PI
Experimental Therapeutics (ET)$48,553
P30 · FY2019 · CA · contact PI
Experimental Therapeutics (ET)$48,553
P30 · FY2018 · CA · contact PI
Experimental Therapeutics (ET)$34,975
P30 · FY2018 · CA · contact PI
Experimental Therapeutics (ET)$11,110
P30 · FY2018 · CA · contact PI
Experimental Therapeutics (ET)$6,943
P30 · FY2018 · CA · contact PI
Inhibition of Pim kinases in acute myeloid leukemia$0
I01 · FY2018 · VA · contact PI
Inhibition of Pim kinases in acute myeloid leukemia$0
I01 · FY2017 · VA · contact PI
Experimental Therapeutics (ET)$125,542
P30 · FY2016 · CA · contact PI
Inhibition of Pim kinases in acute myeloid leukemia$0
I01 · FY2016 · VA · contact PI
Inhibition of Pim kinases in acute myeloid leukemia$0
I01 · FY2015 · VA · contact PI
MDR Gene Polymorphisms in AML$152,990
R21 · FY2008 · CA · contact PI
MDR Gene Polymorphisms in AML$192,621
R21 · FY2007 · CA · contact PI
Broad Spectrum MDR Modulation in AML$142,812
R21 · FY2004 · CA
Broad Spectrum MDR Modulation in AML$141,566
R21 · FY2003 · CA
IRINOTECAN AND CYTARABINE IN ACUTE MYELOID LEUKEMIA$272,288
R21 · FY2001 · CA
IRINOTECAN AND CYTARABINE IN ACUTE MYELOID LEUKEMIA$268,944
R21 · FY2000 · CA